title: Efficacy and safety of prolonged-release OROS methylphenidate in adults with attention deficit/hyperactivity disorder: a 13-week, randomized, double-blind, placebo-controlled, fixed-dose study.
abstract: OBJECTIVE
  Methylphenidate (MPH) is effective for adults with attention-deficit/hyperactivity disorder (ADHD). This study aimed to evaluate the efficacy and safety of OROS MPH in adults with ADHD.
  
  
  METHODS
  Randomized, double-blind study; 279 subjects received OROS MPH 54 or 72 mg/day, or placebo, for 13 weeks. Primary endpoint was the Conners' Adult ADHD Rating Scale - Screening Version (CAARS-O:SV). Secondary outcomes included CAARS Self Report - Short Version (CAARS-S:S), Sheehan Disability Scale (SDS) and ADHD Impact Module - Adult (AIM-A).
  
  
  RESULTS
  Improvements in CAARS-O:SV were significantly greater with OROS MPH 72 mg vs. placebo (P = 0.0024). CAARS-S:S scores decreased significantly vs. placebo in both OROS MPH arms (P < 0.05). There was no significant change in SDS score from baseline in either treatment arm, although significant benefit vs. placebo was observed on several AIM-A subscales. Treatment was well tolerated.
  
  
  CONCLUSIONS
  OROS MPH provided overall benefits in the treatment of adults with ADHD.
authors: Department of Psychiatry, Hospital Universitari Vall d'Hebron and Department of Psychiatry and Legal Medicine, Universitat Autònoma de Barcelona, Barcelona, Spain. mcasasb@gmail.com
authors: Miguel
authors: M
authors: Casas
authors: Michael
authors: M
authors: Rösler
authors: J J
authors: JJ
authors: Sandra Kooij
authors: Ylva
authors: Y
authors: Ginsberg
authors: Josep Antoni
authors: JA
authors: Ramos-Quiroga
authors: Steffen
authors: S
authors: Heger
authors: Joris
authors: J
authors: Berwaerts
authors: Joachim
authors: J
authors: Dejonckheere
authors: Erik
authors: E
authors: van der Vorst
authors: Barbara
authors: B
authors: Schäuble
mesh_terms: D000293:Adolescent; D000328:Adult; D001289:Attention Deficit Disorder with Hyperactivity / Q000188:drug therapy*; D000697:Central Nervous System Stimulants / Q000627:therapeutic use*; D003692:Delayed-Action Preparations; D004311:Double-Blind Method; D005260:Female; D006801:Humans; D008297:Male; D008774:Methylphenidate / Q000627:therapeutic use*; D008875:Middle Aged; D009995:Osmosis; D016896:Treatment Outcome; D055815:Young Adult
chemical_list: D000697:Central Nervous System Stimulants; D003692:Delayed-Action Preparations; D008774:Methylphenidate